Zenas Biopharma has acquired global rights to develop BTK inhibitor orelabrutinib to treat progressive forms of multiple ...

Women with multiple sclerosis, particularly after menopause, experience a higher risk of relapse-independent worsening, ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), ...

A preclinical study by biomedical scientists at the University of California, Riverside, has shown why some people with ...

Researchers have identified a rare type of brain cell that may drive the chronic inflammation and neurodegeneration seen in progressive multiple sclerosis (MS).

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may ...

Broad rim lesions have been identified as a new biomarker for rapid multiple sclerosis progression, offering key insights ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

FRIDAY, Oct. 3, 2025 (HealthDay News) — Menopause does not increase symptoms and disability among women with multiple ...

Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase III trials in relapsing MS will further evaluate the effect of vidofludimus ...

Discover a new study showing that menopause does not accelerate disability in women with multiple sclerosis, offering ...

With FDA-requested toxicology reports in hand, Quantum is preparing to seek clearance for stating the first trial of Lucid-MS ...